FibroGen, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
FibroGen, Inc. - overview
Established
1993
Location
San Francisco, CA, US
Primary Industry
Biotechnology
About
FibroGen, Inc. is a US-based biopharmaceutical company dedicated to developing innovative therapies for serious medical conditions, particularly focusing on anemia and cancer treatment. FibroGen, Inc. , founded in 1993, is primarily engaged in biopharmaceutical research and development, with headquarters in San Francisco, US.
The company's founder, Rory Riggs, has a background in biotechnology and has been involved in the establishment of other companies. In November 2014, FibroGen raised USD 62. 00 mn through a PIPE funding round led by AstraZeneca, marking a significant milestone in its funding history. FibroGen, Inc.
specializes in developing therapies for conditions such as anemia and pancreatic cancer. Their primary products include Roxadustat for treating anemia related to chronic kidney disease and chemotherapy-induced anemia, and FG-3246, which is in the clinical trial phase. These products target specific biological pathways to enhance treatment outcomes for patients. FibroGen markets its offerings in the US and China, serving healthcare institutions and pharmacies to ensure access to their therapies.
In the most recent fiscal year 2024, FibroGen reported a revenue of USD 29. 62 mn and an EBITDA of USD -147. 72 mn. The company generates revenue through the sales of its pharmaceutical products and collaborations, primarily focusing on its flagship product, Roxadustat, to address the anemia market.
FibroGen plans to expand its product line through the development of new therapies, aiming to launch FG-3246 in upcoming phases. The company is targeting expansion into additional markets within Asia and Europe, looking to establish a foothold by 2025. The funding raised in the latest PIPE round will be used to support these initiatives and enhance their research capabilities.
Current Investors
Sigma Capital Group, T Rowe Price, Daiwa Corporate Investment
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.fibrogen.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
FibroGen, Inc. - financials
| Fiscal Year Ended | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 137,601,000 | 180,828,000 | 179,577,000 | 125,668,000 | 212,958,000 | 256,577,000 | 176,319,000 | 235,309,000 | 140,734,000 | - | - | - |
| % Revenue Growth (YoY) | - | 31.4% | (0.7%) | (30.0%) | 69.5% | 20.5% | (31.3%) | 33.5% | (40.2%) | - | - | - |
| EBITDA (USD) | (44,974,000) | (68,949,000) | (44,885,000) | (114,666,000) | (80,173,000) | (71,527,000) | (169,833,000) | (273,721,000) | (290,421,000) | - | - | - |
| Operating Income (USD) | (50,102,000) | (77,625,000) | (53,654,000) | (122,609,000) | (86,693,000) | (89,314,000) | (191,880,000) | (288,530,000) | (301,025,000) | - | - | - |
| Operating Margin | (36.4%) | (42.9%) | (29.9%) | (97.6%) | (40.7%) | (34.8%) | (108.8%) | (122.6%) | (213.9%) | - | - | - |
| % EBITDA Margin | (32.7%) | (38.1%) | (25.0%) | (91.2%) | (37.6%) | (27.9%) | (96.3%) | (116.3%) | (206.4%) | - | - | - |
| NET Income (USD) | (59,504,000) | (85,779,000) | (61,680,000) | (126,203,000) | (86,420,000) | (76,970,000) | (189,291,000) | (290,023,000) | (293,654,000) | - | - | - |
| % Net Margin | (43.2%) | (47.4%) | (34.3%) | (100.4%) | (40.6%) | (30.0%) | (107.4%) | (123.3%) | (208.7%) | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.